Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $17.41 Analyst target: $57.00 Upside: 227.40%
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 / neu-expressing cancers. The company is headquartered in Stafford, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.